RU
Rubicon Research Ltd (RUBICON)
₹1,610.50
Mkt cap
₹26,660 Cr
P/E ratio
92.50
P/B
20.62
Div yield
0.09%
ROE
27.00%
ROCE
28.40%
EPS (TTM)
₹17.41
Book value
₹78
52W range
571–1,899
Sector
Healthcare
Price history
Previous close
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations. [1]
NSE RUBICONBSE 544578
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−15.19% from high₹1,611
₹571+182.17% from low₹1,899
Current
₹1,610.50
Prev close
₹1,559.30
Day
+3.28%
Price performance
1D
+3.57%
1W
+13.38%
1M
+0.37%
3M
+7.65%
6M
+65.56%
1Y
+169.10%
YTD
+143.50%
Financials
Revenue, profit & margin
P/E ratio
92.5×
RUBICON is 169% above the sector median of 34.4×
RUBICON92.5×
Sector median34.4×
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 | |
| Expenses | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 | |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 | |
| OPM % | 21% | 22% | 20% | 22% | 23% | 23% | 23% | 24% | |
| Other Income | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 | |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 | |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 | |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 | |
| Tax % | 30% | 28% | 29% | 27% | 25% | 20% | 22% | 23% | |
| Net Profit | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 | |
| EPS in Rs | 2.27 | 2.50 | 2.35 | 2.81 | 3.49 | 4.42 | 4.65 | 5.13 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
5 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +10.96% · closed higher next day 4 of last 4
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.25%Promoter
Promoters51.25%8.51
FIIs9.01%1.49
DIIs15.73%6.30
Public24.03%0.74
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Rubicon Research | ₹1,610.50 | 92.50 | 26,660 | 0.09% | 85 | +95.80% | 534 | +51.59% | 28.35% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports1
Concall transcripts11
Credit ratings2
Announcements5
Outcome Of USFDA Inspection Of Rubicon Research Ltd, Manufacturing Facility In Ambernath, India. 30 Oct - USFDA inspection at Ambernath facility concluded on 29 Oct 2026 with five procedural Form 483 observations.Intimation Regarding Q2 Earnings Conference Call. 28 Oct - Earnings conference call scheduled for November 5, 2026 to discuss Q2FY27 and half-year results.Board Meeting Intimation for Q 2 Ended September, 2026. 27 Oct - Board meeting on November 5, 2026 to approve Q2/H1 FY27 unaudited results; trading window closedOctober 1.Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 -US FDA Inspection Of The Company''s Manufacturing Facility In Satara, Maharashtra, India. 9 Oct - US FDA inspected Satara facility Oct. 5-9, 2026; Form 483 issued with one procedural observation.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.